decitabine,venetoclax
mgi pharma,supergen,roche,abbvie
['leukemia', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'leusm', 'decitabine']
#ash22 #leusm xie: ven+decitabine in young pts (&lt;60yo) with newly diagnosed eln adverse risk aml, n=42. orr 78.6%, lower (55.6%) with monocytic phenotype. cr 69% in this adverse risk pop appears higher than cr with intensive chemo (43%). some take &gt;1 cycle to max resp, esp tp53m. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)